10 Best Multibagger Penny Stocks to Buy According to Billionaires

4. Xeris Biopharma Holdings Inc. (NASDAQ:XERS)

Number of Billionaire Holders: 7

1-Year Gain as of April 21: 130.90%

Share Price as of April 21: $4.11

Xeris Biopharma Holdings Inc. (NASDAQ:XERS) is a biopharmaceutical company that develops and commercializes innovative therapies across endocrinology, neurology, and gastroenterology segments. The company focuses on developing products using its proprietary XeriSol and XeriJect technology platforms. The stock is up by 130.90% over the past year thanks to continued momentum in its commercial business.

Recorlev is driving growth in the commercial business for the treatment of Cushing’s syndrome, which has shown 118% growth; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis. The three products were the catalyst behind Xeris Biopharma’s delivery of strong full-year 2024 results, characterized by a record revenue of $203 million, an improvement from $163.9 million in 2023.

In addition, Xeris Biopharma Holdings Inc. (NASDAQ:XERS) sentiments significantly increased the company’s net loss, narrowing to $54.8 million in FY2024 from $62.3 million in 2023. The company boasts of an impressive revenue growth trajectory that has reached 22.7% over the past 12 months. It’s already projecting a 30% revenue growth in 2025 of between $255 and $275 million, driven by the substantial upside potential of XP8121, a treatment for hypothyroidism.